Thomas Jefferson University · Microbiology & ImmunologyVaccine Development for Emerging Infectious Diseases Lab
Matthias Johannes Schnell · Philadelphia, Pennsylvania
Research Focus
Dr. Matthias Johannes Schnell's lab focuses on developing a new vaccine against the Crimean-Congo hemorrhagic fever virus (CCHFV), a dangerous pathogen with high fatality rates. The lab uses innovative vaccine platforms based on inactivated rabies and vesicular stomatitis viruses to generate protective immunity against CCHFV. They work on understanding how these vaccines work and aim to create a safer method for vaccine testing using animal models, ultimately contributing to public health safety.
CCHFVvaccine developmentrhabdovirusesemerging infectious diseasesanimal modelsimmunogenicityviral vectorspublic healthhemorrhagic fever
Research Aims
3AIM 01Characterize Rhabdoviral-based CCHFV vaccine constructs.
AIM 02Determine rhabdoviral-based CCHFV vaccine mechanism of protection.
AIM 03Evaluate the protective efficacy of rhabdoviral-based vaccine candidates in lethal challenge models.
Skills the Lab Values
vaccine characterizationmouse modelsimmunological assaysflow cytometrybiological assaysantibody testingviral challenge modelsbacterial culture techniquesgenetic engineering
Output against the department
Publications190top 34% of dept.167th of 486
this lab
most publishedleast published
Citations11ktop 34% of dept.165th of 486
this lab
most citedleast cited
Career totals from OpenAlex, compared against labs that share a department. A department spans everything from one paper to tens of thousands, so bar heights are on a log scale — otherwise the largest lab would flatten every other bar to a line.